NMPA approves Gilead's new hepatitis B drug phosphatinofa (JXHL1700186) for the treatment of chronic hepatitis B
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Gilead hepatitis Bnew drug(http://phosphatinofa tablets (TAF) of the new drug application (JXHL1700186) was approved by the NationalDrug(http://Administration (NMPA) for the treatment of adults and adolescents (over 12 years of age, weight over 35 kg) chronic hepatitis BGilead first submitted an application for a special approval in February 2014 in China for theinternational multi-center clinicaltrial(http:// of the International Multi-Center ClinicalTrial(http:// in ChinaGilead received the approval of the International Multi-Center Clinical Trial in April 2015 and has registered three studies in China in 2015 (CTR20150267; CTR20150268; CTR20150269)about the phosphatinofvirpyroproflopyria (tinoforaola, TAF), is the pre-drug of the clinical standard drug TDF of hepatitis B, because it has high blood stability and can effectively deliver to liver cells, so TAF can play a similar effect with the latter at a dose less than one-tenth (25 mg/300)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
